Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction?

Mohammad Javad Hajipour*, Hossein Mohammad-Beigi, Iraj Nabipour, Negar Mahmoudi, Morteza Azhdarzadeh, Hossein Derakhshankhah, Dina El Dawud, Reza Mohammadinejad, Daniel Otzen

*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Abstract

Nanotechnology-based approaches have shown promising potential to overcome the challenges associated with current therapeutic/diagnostic approaches and offer exciting solutions to improve the quality of life of Alzheimer's Disease (AD) patients. Unfortunately, thus far they have failed in clinical translation. These disappointing results question whether nanotechnology-based therapeutic strategies are heading in the right direction. Here, we re-consider the problems and current therapeutic approaches from new angles and suggest what might have been overlooked in advanced AD therapy.

Original languageEnglish
Article number100983
JournalNano Today
Volume35
IssueDecember
Number of pages5
ISSN1748-0132
DOIs
Publication statusPublished - 2020

Keywords

  • Alzheimer's disease
  • Fibrillation
  • Nanoparticles
  • Nanotechnology

Fingerprint

Dive into the research topics of 'Amyloid fibril inhibition, acceleration, or fragmentation: Are nano-based approaches advance in the right direction?'. Together they form a unique fingerprint.

Cite this